C4 Therapeutics, Inc.
CCCC
Last
$3.16
Day
+10.9%
1y
+18.3%
5y
-93.7%
52w
-44.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0525d
EMA 21
3.15
EMA 50
3.41
EMA 200
3.28
20d high
-20.6%
5y high
-94.2%
5y range
4th
Positions held
Your positionsCCCC isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$3.24
Stop
$2.52
Stop distance
20.3%
Target vs last
+2.5%
Fundamentals
| Market cap | $350.62M | Enterprise value | $153.82M | Trailing P/E | — | Forward P/E | -2.86 |
| PEG | — | Price / book | 1.42 | Beta | 3.08 | Dividend yield | 0.00% |
| Revenue growth | 2.8% | Earnings growth | — | Gross margin | 86.3% | Operating margin | -4.0% |
| Profit margin | -2.9% | ROE | -48.1% | ROA | -19.3% | Debt / equity | 0.23 |
| Current ratio | 5.45 | Free cash flow | -$43.66M | Analyst recommendation | strong_buy | Mean target | $13.33 |
| 52w high | $5.17 | 52w low | $1.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $6.6M | $6.2M | $11.0M | $11.2M | $6.5M | — |
| Op margin | -397.9% | -451.6% | -210.1% | -210.9% | -441.0% | — |
| Net income | -$23.6M | -$25.1M | -$20.5M | -$32.2M | -$26.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$26.4M | -$27.8M | -$23.1M | -$23.7M | -$28.5M | — |
- Revenue +8% vs prior quarter ($6.6M vs $6.2M).
- Operating margin expanded to -397.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | — |
| Op margin | -290.7% | -329.3% | -669.8% | -416.6% | — |
| Net income | -$105M | -$105M | -$132M | -$128M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$104M | -$117M | -$139M | -$130M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-08-21 · Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
2026-08-11 · C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 · C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-10 · C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patternsCCCC · daily-13.9% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin